May 2, 2018
Pacific Biosciences of California, Inc. Announces First Quarter 2018 Financial Results

MENLO PARK, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its first quarter ended March 31, 2018.

Total revenue for the first quarter of 2018 was $19.4 million, compared to $24.9 million for the first quarter of 2017.

Gross profit for the first quarter of 2018 was $7.3 million, resulting in a gross margin of 38%. Gross profit for the first quarter of 2017 was $8.9 million, resulting in a gross margin of 36%.

Operating expenses for the first quarter of 2018 totaled $31.2 million, compared to $32.2 million for the first quarter of 2017. Operating expenses for the first quarter of 2018 and 2017 included non-cash stock-based compensation of $4.6 million and $4.5 million, respectively.

Net loss for the first quarter of 2018 was $24.2 million, compared to $23.9 million for the first quarter of 2017.

Cash, cash equivalents and investments, excluding restricted cash, at March 31, 2018 totaled $79.3 million, compared to $62.9 million at December 31, 2017.

Quarterly Conference Call Information

Management will host a quarterly conference call to discuss its first quarter ended March 31, 2018 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330,using an Audience Passcode of 936-7938. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contact:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

           
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)
           
  Quarter Ended March 31,
  2018     2017  
Revenue:          
Product revenue $  16,282     $  21,294  
Service and other revenue    3,080        3,621  
     Total revenue    19,362        24,915  
Cost of Revenue:          
Cost of product revenue    9,019        11,362  
Cost of service and other revenue    3,047        4,616  
     Total cost of revenue    12,066        15,978  
          Gross profit    7,296        8,937  
Operating Expense:          
Research and development    16,311        16,971  
Sales, general and administrative    14,934        15,265  
     Total operating expense    31,245        32,236  
Operating loss    (23,949 )      (23,299 )
Interest expense    (581 )      (838 )
Other income (expense), net    351        270  
Net loss $  (24,179 )   $  (23,867 )
Basic and diluted net loss per share $  (0.20 )   $  (0.26 )
Shares used in computing basic and diluted net loss per share    123,768        92,970  
               


           
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
 (amounts in thousands)
           
  March 31,   December 31,
  2018   2017
Assets      
Cash and investments $  79,260   $  62,872
Accounts receivable    8,452      13,433
Inventory    25,930      23,065
Prepaid and other current assets    2,057      2,249
Property and equipment    36,704      37,920
Long-term restricted cash    4,500      4,500
Other long-term Assets    46      45
Total Assets $  156,949   $  144,084
           
Liabilities and Stockholders' Equity          
Accounts payable $  8,567   $  9,093
Accrued expenses    10,243      12,618
Deferred service revenue    7,087      7,394
Deferred rent    14,285      14,453
Other liabilities    145      605
Financing derivative    12      183
Notes payable    13,872      13,635
Stockholders' equity    102,738      86,103
Total Liabilities and Stockholders' Equity $  156,949   $  144,084
           

Primary Logo

Source: Pacific Biosciences, Inc.

STOCK QUOTE

Copyright Nasdaq. Minimum 15 minutes delayed.

Investor
Contact

Pacific Biosciences

1305 O’Brien Drive

Menlo Park, CA  94025

ir@pacb.com